<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neuroophthalmol</journal-id><journal-id journal-id-type="iso-abbrev">J Neuroophthalmol</journal-id><journal-id journal-id-type="publisher-id">wno</journal-id><journal-title-group><journal-title>Journal of Neuro-Ophthalmology</journal-title></journal-title-group><issn pub-type="ppub">1070-8022</issn><issn pub-type="epub">1536-5166</issn><publisher><publisher-name>Journal of Neuro-Ophthalmology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23263355</article-id><article-id pub-id-type="pmc">3658961</article-id><article-id pub-id-type="publisher-id">WNO200740</article-id><article-id pub-id-type="doi">10.1097/WNO.0b013e318272c643</article-id><article-id pub-id-type="art-access-id">00008</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Contribution</subject></subj-group></article-categories><title-group><article-title>Effects of Idebenone on Color Vision in Patients With Leber Hereditary Optic Neuropathy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rudolph</surname><given-names>Guenther</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Dimitriadis</surname><given-names>Konstantinos</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Büchner</surname><given-names>Boriana</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Heck</surname><given-names>Suzette</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Al-Tamami</surname><given-names>Jasmina</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Seidensticker</surname><given-names>Florian</given-names></name><degrees>MD</degrees></contrib><contrib contrib-type="author"><name><surname>Rummey</surname><given-names>Christian</given-names></name><degrees>PhD</degrees></contrib><contrib contrib-type="author"><name><surname>Leinonen</surname><given-names>Mika</given-names></name><degrees>MSc</degrees></contrib><contrib contrib-type="author"><name><surname>Meier</surname><given-names>Thomas</given-names></name><degrees>PhD</degrees></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Klopstock</surname><given-names>Thomas</given-names></name><degrees>MD</degrees></contrib></contrib-group><aff>Department of Ophthalmology (GR, FS), Ludwig-Maximilians-University, Munich, Germany; Department of Neurology (KD, BB, SH, JA-T, TK), Friedrich-Baur-Institute, Ludwig-Maximilians-University, Munich, Germany; Santhera Pharmaceuticals (CR, TM), Liestal, Switzerland; and 4Pharma (ML), Stockholm, Sweden.</aff><pub-date pub-type="ppub"><month>3</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>27</day><month>2</month><year>2013</year></pub-date><volume>33</volume><issue>1</issue><fpage>30</fpage><lpage>36</lpage><permissions><copyright-statement>Copyright © 2012 by North American Neuro-Ophthalmology Society</copyright-statement><copyright-year>2012</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivitives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="wno-33-30.pdf"></self-uri><abstract><sec><title><offsets xml_i="3846" xml_f="3857" txt_i="11" txt_f="22">Background:</offsets></title><p><offsets xml_i="3868" xml_f="4150" txt_i="23" txt_f="305">The authors investigated the correlation of protan and tritan color vision with disease characteristics in Leber hereditary optic neuropathy (LHON). The authors also characterized the therapeutic potential of idebenone in protecting patients from developing dyschromatopsia in LHON.</offsets></p></sec><sec><title><offsets xml_i="4172" xml_f="4180" txt_i="307" txt_f="315">Methods:</offsets></title><p><offsets xml_i="4191" xml_f="4605" txt_i="316" txt_f="727">Color contrast data of 39 LHON patients participating in a randomized, double-blind placebo-controlled intervention study were evaluated. Patients reported disease onset &lt;5 years before enrolment and were genetically confirmed. Protan and tritan color contrast sensitivity was measured using a computer graphics method in patients receiving idebenone (Catena; 900 mg/d; N = 28) or placebo (N = 11) for 6 months.</offsets></p></sec><sec><title><offsets xml_i="4627" xml_f="4635" txt_i="729" txt_f="737">Results:</offsets></title><p><offsets xml_i="4646" xml_f="5043" txt_i="738" txt_f="1126">Mean age of patients was 28.1 years, 87.2% were men, 76.9% carried the m11778G&gt;A mutation, and mean duration since onset was 2 years. Assessing protan and tritan color vision at baseline revealed a high degree of color confusion even in young patients (&lt;25 years) and with a short history of disease (&lt;1 year). Treatment with idebenone improved tritan color vision compared with placebo (</offsets><italic><offsets xml_i="5051" xml_f="5052" txt_i="1126" txt_f="1127">P</offsets></italic><offsets xml_i="5061" xml_f="5310" txt_i="1127" txt_f="1373"> = 0.008 at week 24); a similar trend was seen for protan. The effect of idebenone was most prominent in patients with discordant visual acuity (interocular difference of logMAR &gt;0.2). In this subgroup, the treatment effect at week 24 was 20.4% (</offsets><italic><offsets xml_i="5318" xml_f="5319" txt_i="1373" txt_f="1374">P</offsets></italic><offsets xml_i="5328" xml_f="5399" txt_i="1374" txt_f="1445"> = 0.005) in favor of idebenone for the tritan color domain and 13.5% (</offsets><italic><offsets xml_i="5407" xml_f="5408" txt_i="1445" txt_f="1446">P</offsets></italic><offsets xml_i="5417" xml_f="5449" txt_i="1446" txt_f="1478"> = 0.067) for the protan domain.</offsets></p></sec><sec><title><offsets xml_i="5471" xml_f="5482" txt_i="1480" txt_f="1491">Conclusion:</offsets></title><p><offsets xml_i="5493" xml_f="5718" txt_i="1492" txt_f="1717">This study confirms that protan and tritan color confusion is an early symptom in LHON. Treatment with idebenone can protect from loss of color vision, particularly in patients who are at imminent risk of further vision loss.</offsets></p></sec></abstract><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><offsets xml_i="5900" xml_f="6109" txt_i="1726" txt_f="1935">Leber hereditary optic neuropathy (LHON; MIM 535000) causes progressive and mostly irreversible loss of central vision in one eye, followed by a similar loss of vision in the fellow eye within days to months (</offsets><xref ref-type="bibr" rid="R1 R2 R3"><offsets xml_i="6146" xml_f="6149" txt_i="1935" txt_f="1938">1–3</offsets></xref><offsets xml_i="6156" xml_f="6619" txt_i="1938" txt_f="2401">). The painless loss in central visual acuity (VA) is characterized by an enlarging centrocecal scotoma and loss of color vision. Dyschromatopsia in LHON has been described predominantly as red–green (protan) defect with concomitant loss of blue–yellow (tritan) color contrast sensitivity. Dyschromatopsia results from function loss primarily in small-caliber retinal ganglion cells constituting the papillomacular bundle of the retinal nerve fiber layer (RNFL) (</offsets><xref ref-type="bibr" rid="R4 R5"><offsets xml_i="6653" xml_f="6656" txt_i="2401" txt_f="2404">4,5</offsets></xref><offsets xml_i="6663" xml_f="6824" txt_i="2404" txt_f="2565">). The smallest fibers in the retina belonging to the parvocellular neurons and mediating red–green color vision are at highest risk of functional loss in LHON (</offsets><xref ref-type="bibr" rid="R6 R7"><offsets xml_i="6858" xml_f="6861" txt_i="2565" txt_f="2568">6,7</offsets></xref><offsets xml_i="6868" xml_f="7008" txt_i="2568" txt_f="2708">). Blue–yellow color vision predominantly is carried by the koniocellular pathway, which seems to be somewhat less affected by the disease (</offsets><xref ref-type="bibr" rid="R7"><offsets xml_i="7039" xml_f="7040" txt_i="2708" txt_f="2709">7</offsets></xref><offsets xml_i="7047" xml_f="7157" txt_i="2709" txt_f="2819">), explaining the subtle differences in the development of protan and tritan color confusion in LHON patients.</offsets></p><p><offsets xml_i="7164" xml_f="7416" txt_i="2820" txt_f="3063">LHON is caused in most patients by 1 of 3 primary pathogenic mutations of the mitochondrial DNA (mtDNA: m.11778G&gt;A, m.14484T&gt;C, m.3460G&gt;A), all of which affect complex I (NADH–ubiquinone–oxidoreductase) of the mitochondrial respiratory chain (</offsets><xref ref-type="bibr" rid="R1 R8 R9"><offsets xml_i="7453" xml_f="7458" txt_i="3063" txt_f="3068">1,8,9</offsets></xref><offsets xml_i="7465" xml_f="7623" txt_i="3068" txt_f="3226">). These mutations lead to a defect of ATP synthesis accompanied by increased oxidative stress causing retinal ganglion cell dysfunction and eventually loss (</offsets><xref ref-type="bibr" rid="R10 R11"><offsets xml_i="7659" xml_f="7664" txt_i="3226" txt_f="3231">10,11</offsets></xref><offsets xml_i="7671" xml_f="7984" txt_i="3231" txt_f="3535">). Patients with the m.14484T&gt;C mutation generally tend to have milder disease progression with a 37%–71% chance of some degree of visual improvement, whereas patients with the m.11778G&gt;A and m.3460G&gt;A mutations have a worse prognosis with a much lower (approximately 4%) chance of spontaneous recovery (</offsets><xref ref-type="bibr" rid="R2 R12 R13"><offsets xml_i="8023" xml_f="8030" txt_i="3535" txt_f="3542">2,12,13</offsets></xref><offsets xml_i="8037" xml_f="8039" txt_i="3542" txt_f="3544">).</offsets></p><p><offsets xml_i="8046" xml_f="8235" txt_i="3545" txt_f="3734">The short-chain synthetic benzoquinone idebenone (2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone) was recommended in a recent expert opinion as a potential treatment for LHON (</offsets><xref ref-type="bibr" rid="R3"><offsets xml_i="8266" xml_f="8267" txt_i="3734" txt_f="3735">3</offsets></xref><offsets xml_i="8274" xml_f="8309" txt_i="3735" txt_f="3770">), based on isolated case reports (</offsets><xref ref-type="bibr" rid="R14 R15 R16 R17"><offsets xml_i="8353" xml_f="8358" txt_i="3770" txt_f="3775">14–17</offsets></xref><offsets xml_i="8365" xml_f="8413" txt_i="3775" txt_f="3823">) and a small retrospective open-labeled study (</offsets><xref ref-type="bibr" rid="R18"><offsets xml_i="8445" xml_f="8447" txt_i="3823" txt_f="3825">18</offsets></xref><offsets xml_i="8454" xml_f="8669" txt_i="3825" txt_f="4040">). The therapeutic potential of idebenone in LHON has been further investigated by our group in a randomized, double-blind placebo-controlled study (the Rescue of Hereditary Optic Disease Outpatient Study [RHODOS] (</offsets><xref ref-type="bibr" rid="R19"><offsets xml_i="8701" xml_f="8703" txt_i="4040" txt_f="4042">19</offsets></xref><offsets xml_i="8710" xml_f="8757" txt_i="4042" txt_f="4089">)) and independently in a retrospective study (</offsets><xref ref-type="bibr" rid="R20"><offsets xml_i="8789" xml_f="8791" txt_i="4089" txt_f="4091">20</offsets></xref><offsets xml_i="8798" xml_f="9111" txt_i="4091" txt_f="4404">). These studies confirmed the therapeutic potential of idebenone in preventing loss of vision, particularly in patients with discordant interocular VA (i.e., one eye more severely affected than the other eye) and at imminent risk of further vision loss as well as by facilitating and accelerating recovery of VA.</offsets></p><p><offsets xml_i="9118" xml_f="9786" txt_i="4405" txt_f="5073">In this study, we investigated the red–green (protan) and blue–yellow (tritan) color contrast sensitivity, which is affected early in the course of LHON, in a subgroup of LHON patients enrolled in the RHODOS study. The first objective was to further characterize color vision in LHON patients using the baseline data from the study, particularly investigating the degree of dyschromatopsia in relation to age, disease history, and VA. The second objective was to describe the therapeutic benefit of idebenone treatment on color vision during the 6-month treatment period of the RHODOS study by comparison of the idebenone-treated group with patients receiving placebo.</offsets></p><sec sec-type="methods" id="s1"><title><offsets xml_i="9829" xml_f="9836" txt_i="5074" txt_f="5081">METHODS</offsets></title><sec id="s1-1"><title><offsets xml_i="9866" xml_f="9874" txt_i="5082" txt_f="5090">Patients</offsets></title><p><offsets xml_i="9885" xml_f="10056" txt_i="5091" txt_f="5262">We obtained color contrast sensitivity data in a subgroup of 39 LHON patients enrolled in a prospective, randomized, double-blind placebo-controlled study (RHODOS study; 
</offsets><ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov"><offsets xml_i="10125" xml_f="10143" txt_i="5262" txt_f="5280">ClinicalTrials.gov</offsets></ext-link><offsets xml_i="10154" xml_f="10352" txt_i="5280" txt_f="5469"> identifier: NCT00747487). Patients harbored 1 of 3 primary mtDNA mutations (m.11778G&gt;A, m.14484T&gt;C, or m.3460G&gt;A) and had vision loss caused by LHON within 5 years before study enrolment (</offsets><xref ref-type="bibr" rid="R19"><offsets xml_i="10384" xml_f="10386" txt_i="5469" txt_f="5471">19</offsets></xref><offsets xml_i="10393" xml_f="10762" txt_i="5471" txt_f="5837">). The study had ethical and institutional review board approval, and all patients gave written informed consent. Patients were stratified by disease history (onset ≤1 year vs &gt;1 year) and mtDNA mutation and randomized to receive idebenone (Catena; Santhera Pharmaceuticals) 900 mg/d (300 mg three times a day during meals) (N = 28) or placebo (N = 11) for 24 weeks.</offsets></p></sec><sec id="s1-2"><title><offsets xml_i="10794" xml_f="10838" txt_i="5839" txt_f="5883">Color Contrast and Visual Acuity Assessments</offsets></title><p><offsets xml_i="10849" xml_f="11076" txt_i="5884" txt_f="6111">Color contrast sensitivity was measured in the Munich center of the RHODOS study at baseline and weeks 4, 12, and 24 using a computer graphics method specifically developed for the assessment of protan and tritan color vision (</offsets><xref ref-type="bibr" rid="R21"><offsets xml_i="11108" xml_f="11110" txt_i="6111" txt_f="6113">21</offsets></xref><offsets xml_i="11117" xml_f="11822" txt_i="6113" txt_f="6818">). Isoluminant colored optotypes of 4° were generated on a calibrated monitor on a white background and viewed at a distance of 1 m. The color difference between the optotypes and the white background was repeatedly altered until the threshold of visibility was obtained. Random dynamic luminance noise was superimposed on the colored optotype to mask any luminance clues in recognizing the optotype, allowing reliable detection of the red–green (protan) and blue–yellow (tritan) color confusion levels. One hundred percent on the instrument's scale is the maximal color contrast achievable with the monitor's phosphors. Normal levels of color confusion were defined as ≤6% for protan and ≤8% for tritan (</offsets><xref ref-type="bibr" rid="R21"><offsets xml_i="11854" xml_f="11856" txt_i="6818" txt_f="6820">21</offsets></xref><offsets xml_i="11863" xml_f="11865" txt_i="6820" txt_f="6822">).</offsets></p><p><offsets xml_i="11872" xml_f="12298" txt_i="6823" txt_f="7249">VA was determined with an Early Treatment Diabetic Retinopathy Study (ETDRS) chart, and color contrast data were analyzed only for patients who provided valid VA data. Patients with “off-chart” VA and only able to count fingers, detect hand motion, or light perception were assigned logarithm of the minimum angle of resolution (logMAR) values 2.0 (count fingers), 2.3 (hand motion), and 2.6 (light perception), respectively (</offsets><xref ref-type="bibr" rid="R19"><offsets xml_i="12330" xml_f="12332" txt_i="7249" txt_f="7251">19</offsets></xref><offsets xml_i="12339" xml_f="12341" txt_i="7251" txt_f="7253">).</offsets></p></sec><sec id="s1-3"><title><offsets xml_i="12373" xml_f="12393" txt_i="7255" txt_f="7275">Statistical Analyses</offsets></title><p><offsets xml_i="12404" xml_f="12865" txt_i="7276" txt_f="7737">Data were analyzed using the mixed-model repeated measures method. Treatment assignment, visit, interaction between treatment assignment and visit, and prespecified stratification factors (disease onset and mtDNA mutation) were included as fixed factors, with baseline assessment as a covariate and subject as a random factor. Graphical data presentations were generated using TIBCO Spotfire 3.2.1 software. Fisher exact test was applied for responder analyses.</offsets></p></sec></sec><sec sec-type="results" id="s2"><title><offsets xml_i="12920" xml_f="12927" txt_i="7740" txt_f="7747">RESULTS</offsets></title><sec id="s2-1"><title><offsets xml_i="12957" xml_f="12995" txt_i="7748" txt_f="7786">Color Contrast Sensitivity at Baseline</offsets></title><p><offsets xml_i="13006" xml_f="13105" txt_i="7787" txt_f="7886">The mean age of patients for whom color contrast data were obtained was 28 ± 11 (mean ± SD) years (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="13137" xml_f="13144" txt_i="7886" txt_f="7893">Table 1</offsets></xref><offsets xml_i="13151" xml_f="13469" txt_i="7893" txt_f="8202">). The majority of patients were men (87.2%) and carried the m.11778G&gt;A mutation (76.9%). The mean time since onset of vision loss was approximately 2 years (23.5 ± 17.2 months). The mean level of color confusion was &gt;80% for both color domains, with the majority of eyes diagnosed with color confusion &gt;90% (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="13499" xml_f="13509" txt_i="8202" txt_f="8212">Fig. 1A, B</offsets></xref><offsets xml_i="13516" xml_f="13948" txt_i="8212" txt_f="8641">), representing a considerable deficiency in color contrast perception in this patient cohort. Only very few eyes had normal color contrast sensitivity (2.6% for protan and 6.4% for tritan). Graphical presentation of protan against tritan color confusion for all eyes showed that a higher proportion of eyes that already reached &gt;90% color confusion in the protan domain still had residual color perception in the tritan domain (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="13978" xml_f="13985" txt_i="8641" txt_f="8648">Fig. 1C</offsets></xref><offsets xml_i="13992" xml_f="14169" txt_i="8648" txt_f="8822">). In contrast, there were only very few eyes for which residual protan color contrast sensitivity was detectable when they reached &gt;90% color confusion in the tritan domain.</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="14217" xml_f="14224" txt_i="8823" txt_f="8830">TABLE 1</offsets></label><caption><p><offsets xml_i="14244" xml_f="14285" txt_i="8830" txt_f="8871">Clinical characteristics of LHON patients</offsets></p></caption><graphic xlink:href="wno-33-30-g001"></graphic></table-wrap><fig id="F1" position="float"><label><offsets xml_i="14396" xml_f="14402" txt_i="8872" txt_f="8878">FIG. 1</offsets></label><caption><p><offsets xml_i="14422" xml_f="14636" txt_i="8878" txt_f="9092">Distribution of color contrast sensitivities for Leber hereditary optic neuropathy patients at baseline of the Rescue of Hereditary Optic Disease Outpatient Study show markedly elevated color confusion for protan (</offsets><bold><offsets xml_i="14642" xml_f="14643" txt_i="9092" txt_f="9093">A</offsets></bold><offsets xml_i="14650" xml_f="14664" txt_i="9093" txt_f="9107">) and tritan (</offsets><bold><offsets xml_i="14670" xml_f="14671" txt_i="9107" txt_f="9108">B</offsets></bold><offsets xml_i="14678" xml_f="14695" txt_i="9108" txt_f="9125">) color domains. </offsets><bold><offsets xml_i="14701" xml_f="14702" txt_i="9125" txt_f="9126">C</offsets></bold><offsets xml_i="14709" xml_f="14990" txt_i="9126" txt_f="9404">. Correlation of protan and tritan color confusion levels for all eyes (data points are slightly jittered for clarity). Note that many eyes had color confusion of &gt;90% in both color domains resulting in a dense cluster of data points at the upper right hand corner of the graph.</offsets></p></caption><graphic xlink:href="wno-33-30-g002"></graphic></fig><p><offsets xml_i="15060" xml_f="15154" txt_i="9405" txt_f="9499">High degrees of color confusion were seen for both color domains across the entire age range (</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="15184" xml_f="15194" txt_i="9499" txt_f="9509">Fig. 2A, B</offsets></xref><offsets xml_i="15201" xml_f="15717" txt_i="9509" txt_f="10019">) and even young patients up to the age of 20 years had eyes with color confusion of &gt;90%. This is also reflected by the correlation between color vision and disease duration. Although the majority of eyes with less than 30% color confusion in both tritan and protan domains were found in patients with less than 3 years since the time of diagnosis, there were already a considerable proportion of eyes with &gt;90% color confusion within the first year of diagnosis, reflecting rapid progression of the disease (</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="15747" xml_f="15757" txt_i="10019" txt_f="10029">Fig. 2C, D</offsets></xref><offsets xml_i="15764" xml_f="16016" txt_i="10029" txt_f="10275">). Loss of red–green color sensitivity seemed to be more drastic with the majority of eyes either having color contrast confusion &lt;30% or complete loss of protan color sensitivity (&gt;90%), which is typically reached when eyes approach logMAR 1.4 (</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="16046" xml_f="16053" txt_i="10275" txt_f="10282">Fig. 2E</offsets></xref><offsets xml_i="16060" xml_f="16221" txt_i="10282" txt_f="10443">). Loss of blue–yellow color vision appeared to be more gradual, with color confusion between 30% and 80% detected for eyes having a residual VA of logMAR ≥1.4 (</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="16251" xml_f="16258" txt_i="10443" txt_f="10450">Fig. 2F</offsets></xref><offsets xml_i="16265" xml_f="16469" txt_i="10450" txt_f="10654">). Interestingly, there were eyes with remaining, albeit limited, color vision in the tritan domain for patients only able to read letters from the last line of the ETDRS chart or with “off-chart” vision.</offsets></p><fig id="F2" position="float"><label><offsets xml_i="16510" xml_f="16516" txt_i="10655" txt_f="10661">FIG. 2</offsets></label><caption><p><offsets xml_i="16536" xml_f="16595" txt_i="10661" txt_f="10720">Relationship between color contrast sensitivities and age (</offsets><bold><offsets xml_i="16601" xml_f="16602" txt_i="10720" txt_f="10721">A</offsets></bold><offsets xml_i="16609" xml_f="16611" txt_i="10721" txt_f="10723">, </offsets><bold><offsets xml_i="16617" xml_f="16618" txt_i="10723" txt_f="10724">B</offsets></bold><offsets xml_i="16625" xml_f="16646" txt_i="10724" txt_f="10745">), disease duration (</offsets><bold><offsets xml_i="16652" xml_f="16653" txt_i="10745" txt_f="10746">C</offsets></bold><offsets xml_i="16660" xml_f="16662" txt_i="10746" txt_f="10748">, </offsets><bold><offsets xml_i="16668" xml_f="16669" txt_i="10748" txt_f="10749">D</offsets></bold><offsets xml_i="16676" xml_f="16698" txt_i="10749" txt_f="10771">), and visual acuity (</offsets><bold><offsets xml_i="16704" xml_f="16705" txt_i="10771" txt_f="10772">E</offsets></bold><offsets xml_i="16712" xml_f="16714" txt_i="10772" txt_f="10774">, </offsets><bold><offsets xml_i="16720" xml_f="16721" txt_i="10774" txt_f="10775">F</offsets></bold><offsets xml_i="16728" xml_f="16862" txt_i="10775" txt_f="10909">) at baseline of the Rescue of Hereditary Optic Disease Outpatient Study. Each dot represents one eye. Data are shown for the protan (</offsets><bold><offsets xml_i="16868" xml_f="16869" txt_i="10909" txt_f="10910">A</offsets></bold><offsets xml_i="16876" xml_f="16878" txt_i="10910" txt_f="10912">, </offsets><bold><offsets xml_i="16884" xml_f="16885" txt_i="10912" txt_f="10913">C</offsets></bold><offsets xml_i="16892" xml_f="16894" txt_i="10913" txt_f="10915">, </offsets><bold><offsets xml_i="16900" xml_f="16901" txt_i="10915" txt_f="10916">D</offsets></bold><offsets xml_i="16908" xml_f="16922" txt_i="10916" txt_f="10930">) and tritan (</offsets><bold><offsets xml_i="16928" xml_f="16929" txt_i="10930" txt_f="10931">B</offsets></bold><offsets xml_i="16936" xml_f="16938" txt_i="10931" txt_f="10933">, </offsets><bold><offsets xml_i="16944" xml_f="16945" txt_i="10933" txt_f="10934">D</offsets></bold><offsets xml_i="16952" xml_f="16954" txt_i="10934" txt_f="10936">, </offsets><bold><offsets xml_i="16960" xml_f="16961" txt_i="10936" txt_f="10937">F</offsets></bold><offsets xml_i="16968" xml_f="17045" txt_i="10937" txt_f="11014">) color domains. Data points in all graphs are slightly jittered for clarity.</offsets></p></caption><graphic xlink:href="wno-33-30-g003"></graphic></fig></sec><sec id="s2-2"><title><offsets xml_i="17140" xml_f="17194" txt_i="11016" txt_f="11070">Efficacy of Idebenone on Color Vision in LHON Patients</offsets></title><p><offsets xml_i="17205" xml_f="17395" txt_i="11071" txt_f="11261">The decline in protan color contrast sensitivity was larger in the placebo group compared with the group of patients treated with idebenone (estimated mean difference between groups: −6.1%, </offsets><italic><offsets xml_i="17403" xml_f="17404" txt_i="11261" txt_f="11262">P</offsets></italic><offsets xml_i="17413" xml_f="17446" txt_i="11262" txt_f="11295"> = 0.057, for week 12 and −3.9%, </offsets><italic><offsets xml_i="17454" xml_f="17455" txt_i="11295" txt_f="11296">P</offsets></italic><offsets xml_i="17464" xml_f="17488" txt_i="11296" txt_f="11320"> = 0.239, for week 24) (</offsets><xref ref-type="table" rid="T2"><offsets xml_i="17520" xml_f="17527" txt_i="11320" txt_f="11327">Table 2</offsets></xref><offsets xml_i="17534" xml_f="17713" txt_i="11327" txt_f="11506">). In contrast, there was a significant improvement in the tritan color contrast sensitivity in the idebenone group at 12 weeks (estimated mean difference between groups: −14.5%, </offsets><italic><offsets xml_i="17721" xml_f="17722" txt_i="11506" txt_f="11507">P</offsets></italic><offsets xml_i="17731" xml_f="17805" txt_i="11507" txt_f="11581"> = 0.004) and 24 weeks (estimated mean difference between groups: −13.6%; </offsets><italic><offsets xml_i="17813" xml_f="17814" txt_i="11581" txt_f="11582">P</offsets></italic><offsets xml_i="17823" xml_f="17834" txt_i="11582" txt_f="11593"> = 0.008) (</offsets><xref ref-type="table" rid="T3"><offsets xml_i="17866" xml_f="17873" txt_i="11593" txt_f="11600">Table 3</offsets></xref><offsets xml_i="17880" xml_f="17882" txt_i="11600" txt_f="11602">).</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="17930" xml_f="17937" txt_i="11603" txt_f="11610">TABLE 2</offsets></label><caption><p><offsets xml_i="17957" xml_f="18004" txt_i="11610" txt_f="11657">Change in protan color contrast sensitivity (%)</offsets></p></caption><graphic xlink:href="wno-33-30-g004"></graphic></table-wrap><table-wrap id="T3" position="float"><label><offsets xml_i="18122" xml_f="18129" txt_i="11658" txt_f="11665">TABLE 3</offsets></label><caption><p><offsets xml_i="18149" xml_f="18196" txt_i="11665" txt_f="11712">Change in tritan color contrast sensitivity (%)</offsets></p></caption><graphic xlink:href="wno-33-30-g005"></graphic></table-wrap><p><offsets xml_i="18273" xml_f="18673" txt_i="11713" txt_f="12113">Analyzing change in color vision for patients with discordant VA (defined as a difference of logMAR ≥0.2 corresponding to 2 lines on the ETDRS chart between eyes at baseline) revealed a larger difference in the change of both protan and tritan color contrast between placebo- and idebenone-treated patients at weeks 12 and 24, predominantly carried by a more profound worsening in the placebo group (</offsets><xref ref-type="table" rid="T2 T3"><offsets xml_i="18708" xml_f="18722" txt_i="12113" txt_f="12127">Tables 2 and 3</offsets></xref><offsets xml_i="18729" xml_f="18834" txt_i="12127" txt_f="12232">). For patients with discordant VA, there was good correlation between change in VA previously reported (</offsets><xref ref-type="bibr" rid="R19"><offsets xml_i="18866" xml_f="18868" txt_i="12232" txt_f="12234">19</offsets></xref><offsets xml_i="18875" xml_f="18989" txt_i="12234" txt_f="12348">) and change in color contrast sensitivity from baseline to week 24 (correlation between change in VA and protan: </offsets><italic><offsets xml_i="18997" xml_f="18998" txt_i="12348" txt_f="12349">R</offsets></italic><offsets xml_i="19007" xml_f="19008" txt_i="12349" txt_f="12350">
</offsets><sup><offsets xml_i="19013" xml_f="19014" txt_i="12350" txt_f="12351">2</offsets></sup><offsets xml_i="19020" xml_f="19030" txt_i="12351" txt_f="12361"> = 0.532, </offsets><italic><offsets xml_i="19038" xml_f="19039" txt_i="12361" txt_f="12362">P</offsets></italic><offsets xml_i="19048" xml_f="19106" txt_i="12362" txt_f="12417"> &lt; 0.001; correlation between change in VA and tritan: </offsets><italic><offsets xml_i="19114" xml_f="19115" txt_i="12417" txt_f="12418">R</offsets></italic><offsets xml_i="19124" xml_f="19125" txt_i="12418" txt_f="12419">
</offsets><sup><offsets xml_i="19130" xml_f="19131" txt_i="12419" txt_f="12420">2</offsets></sup><offsets xml_i="19137" xml_f="19147" txt_i="12420" txt_f="12430"> = 0.358, </offsets><italic><offsets xml_i="19155" xml_f="19156" txt_i="12430" txt_f="12431">P</offsets></italic><offsets xml_i="19165" xml_f="19178" txt_i="12431" txt_f="12441"> &lt; 0.001).</offsets></p><p><offsets xml_i="19185" xml_f="19612" txt_i="12442" txt_f="12869">Subgroup analysis showed that idebenone was particularly effective in improving tritan color vision in patients younger than 30 years. There was also better efficacy in patients with less than 1 year since diagnosis in the tritan domain, although this did not reach statistical significance, possibly because of the small number of patients in this subgroup. This trend in efficacy was not apparent for the protan color domain.</offsets></p><p><offsets xml_i="19619" xml_f="20035" txt_i="12870" txt_f="13286">The changes in color vision between the idebenone- and placebo-treated patients also were evident by responder analyses. For both color domains, there was a higher proportion of patients with at least one eye improving in color contrast sensitivity for the idebenone group compared with the placebo group (eyes improving in color contrast sensitivity for protan: idebenone, 15 of 56 [27%] and placebo, 2 of 22 [9%], </offsets><italic><offsets xml_i="20043" xml_f="20044" txt_i="13286" txt_f="13287">P</offsets></italic><offsets xml_i="20053" xml_f="20128" txt_i="13287" txt_f="13362"> = 0.127; for tritan: idebenone, 18 of 56 [32%] and placebo, 2 of 22 [9%], </offsets><italic><offsets xml_i="20136" xml_f="20137" txt_i="13362" txt_f="13363">P</offsets></italic><offsets xml_i="20146" xml_f="20395" txt_i="13363" txt_f="13612"> = 0.043). Confining the analysis to patients with discordant VA showed that only idebenone-treated patients reported improved color vision (eyes improving in color contrast sensitivity for protan: idebenone, 8 of 24 [33%] and placebo, 0 of 8 [0%], </offsets><italic><offsets xml_i="20403" xml_f="20404" txt_i="13612" txt_f="13613">P</offsets></italic><offsets xml_i="20413" xml_f="20487" txt_i="13613" txt_f="13687"> = 0.081; for tritan: idebenone, 10 of 24 [42%] and placebo, 0 of 8 [0%], </offsets><italic><offsets xml_i="20495" xml_f="20496" txt_i="13687" txt_f="13688">P</offsets></italic><offsets xml_i="20505" xml_f="20743" txt_i="13688" txt_f="13926"> = 0.035). A similar pattern of greater benefit of idebenone over placebo also was seen for responder analyses requiring a minimum improvement of 5% or 10% in color contrast sensitivity for both protan and tritan domains (data not shown).</offsets></p></sec></sec><sec sec-type="discussion" id="s3"><title><offsets xml_i="20801" xml_f="20811" txt_i="13929" txt_f="13939">DISCUSSION</offsets></title><p><offsets xml_i="20822" xml_f="20988" txt_i="13940" txt_f="14106">Impaired color vision is an early sign of visual impairment in LHON patients, often preceding loss of VA and also detectable in asymptomatic carriers of the disease (</offsets><xref ref-type="bibr" rid="R7 R22"><offsets xml_i="21023" xml_f="21027" txt_i="14106" txt_f="14110">7,22</offsets></xref><offsets xml_i="21034" xml_f="21757" txt_i="14110" txt_f="14830">). We analyzed data from acutely affected LHON patients enrolled in a prospective, randomized, and controlled intervention study to further characterize the relation of impaired red–green (protan) and blue–yellow (tritan) color vision with the patients' disease history. The majority of patients who reported symptom onset not longer than 5 years before the study had already developed considerable color confusion in both color domains. Specifically, substantial color confusion (&gt;90%) was already seen in young patients (≤20 years of age) and in patients with short disease history (≤1 year). Taken together, these findings confirm previous observations that loss of color vision is an early pathological sign in LHON.</offsets></p><p><offsets xml_i="21764" xml_f="21932" txt_i="14831" txt_f="14999">We recently reported the efficacy of idebenone in protecting and facilitating the recovery of VA in LHON patients participating in the placebo-controlled RHODOS study (</offsets><xref ref-type="bibr" rid="R19"><offsets xml_i="21964" xml_f="21966" txt_i="14999" txt_f="15001">19</offsets></xref><offsets xml_i="21973" xml_f="22030" txt_i="15001" txt_f="15058">). In an independent retrospective study, Carelli et al (</offsets><xref ref-type="bibr" rid="R20"><offsets xml_i="22062" xml_f="22064" txt_i="15058" txt_f="15060">20</offsets></xref><offsets xml_i="22071" xml_f="22145" txt_i="15060" txt_f="15134">) also reported efficacy of idebenone, particularly in recovery of vision.</offsets></p><p><offsets xml_i="22152" xml_f="22500" txt_i="15135" txt_f="15483">The main objective of this study was to further characterize the therapeutic potential of idebenone to protect patients from developing dyschromatopsia. Idebenone is capable of shuttling electrons from the cytosol onto the complex III of the mitochondrial electron transport chain, thereby bypassing complex I, which is deficient in LHON patients (</offsets><xref ref-type="bibr" rid="R23"><offsets xml_i="22532" xml_f="22534" txt_i="15483" txt_f="15485">23</offsets></xref><offsets xml_i="22541" xml_f="22709" txt_i="15485" txt_f="15653">). This is of great importance in LHON because of the high energy requirements of retinal ganglion cells and their axons, particularly for their unmyelinated sections (</offsets><xref ref-type="bibr" rid="R4 R5"><offsets xml_i="22743" xml_f="22746" txt_i="15653" txt_f="15656">4,5</offsets></xref><offsets xml_i="22753" xml_f="22755" txt_i="15656" txt_f="15658">).</offsets></p><p><offsets xml_i="22762" xml_f="23960" txt_i="15659" txt_f="16854">The current study investigated the change in color vision in a subgroup of LHON patients enrolled in the RHODOS study. Compared with patients receiving placebo, those treated with idebenone experienced less impairment of protan color vision and a statistically significant improvement in tritan color vision. Of interest is our finding that idebenone was particularly effective in improving/preserving color vision in the subgroup of patients younger than 30 years and in recently diagnosed patients (&lt;1 year since diagnosis). This finding likely reflects the known better potential for recovery in younger-onset LHON patients and the benefit of earlier treatment of the disease. The RHODOS study allowed enrollment of patients diagnosed as long as 5 years earlier, resulting in a mean time since disease onset of approximately 2 years. From the natural history of the disease, it can be expected that the majority of patients will already have optic atrophy and loss of retinal ganglion cells, resulting in a smaller likelihood of benefit, which may have diluted the overall therapeutic effect. Detecting efficacy of idebenone even in this heterogeneous LHON population is therefore remarkable.</offsets></p><p><offsets xml_i="23967" xml_f="24142" txt_i="16855" txt_f="17030">Idebenone also appeared very effective in protection from loss of VA in patients with discordant interocular vision, defining patients at highest risk of further vision loss (</offsets><xref ref-type="bibr" rid="R19"><offsets xml_i="24174" xml_f="24176" txt_i="17030" txt_f="17032">19</offsets></xref><offsets xml_i="24183" xml_f="24296" txt_i="17032" txt_f="17145">). This effect of idebenone in patients with discordant VA was also seen for both protan and tritan color vision.</offsets></p><p><offsets xml_i="24303" xml_f="24594" txt_i="17146" txt_f="17437">The anatomical substrate underlying the preservation of color vision (and VA) in idebenone-treated patients might be stabilization of RNFL thickness. In untreated LHON patients, initial swelling of the RNFL is followed by atrophic thinning, particularly affecting the papillomacular bundle (</offsets><xref ref-type="bibr" rid="R24 R25"><offsets xml_i="24630" xml_f="24635" txt_i="17437" txt_f="17442">24,25</offsets></xref><offsets xml_i="24642" xml_f="24923" txt_i="17442" txt_f="17720">). This dynamic change in RNFL thickness in LHON patients possibly reflects the progressive metabolic crisis occurring in small-diameter retinal ganglion cells. Idebenone preserved the RNFL thickness in patients with a short disease history (i.e. &lt;6 months from symptom onset) (</offsets><xref ref-type="bibr" rid="R19"><offsets xml_i="24955" xml_f="24957" txt_i="17720" txt_f="17722">19</offsets></xref><offsets xml_i="24964" xml_f="25306" txt_i="17722" txt_f="18064">), which is reflected in better preserved VA and color vision. Patients receiving placebo experienced atrophy of the RNFL in the inferior and superior quadrants associated with vision loss and dyschromatopsia. These findings suggest that for maximal benefit, patients with LHON should be treated with idebenone early in their clinical course.</offsets></p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>The authors thank Nick Coppard and Günther Metz (both Santhera Pharmaceuticals) for help in the interpretation of the data, and Professor Geoffrey Arden for very valuable discussions on methods and results of this study. The authors are indebted to the patients who volunteered for this study and they also thank all doctors who have transferred patients into this trial.</p></ack><fn-group><fn fn-type="corresp"><p>Address correspondence to Thomas Klopstock, MD, Department of Neurology, Friedrich-Baur-Institute, Ludwig-Maximilians-University, 80336 Munich, Germany; E-mail: <email>tklopsto@med.lmu.de</email></p></fn><fn fn-type="supported-by"><p>Supported by Santhera Pharmaceuticals (Liestal, Switzerland), the sponsor of the study, and by the German Ministry of Education and Research (BMBF, Bonn, Germany) grant number 01GM0862 to the German network for mitochondrial disorders (mitoNET).</p></fn><fn fn-type="supported-by"><p>Recruiting of patients was supported by use of the patient registry of the German network for mitochondrial disorders (mitoNET), which is funded by the German Ministry of Education and Research (BMBF, Bonn, Germany) grant number 01GM0862.</p></fn><fn fn-type="conflict"><p>C. Rummey and T. Meier are regular employees of Santhera Pharmaceuticals (Liestal, Switzerland), the sponsor of the study. T. Klopstock received research support for this and other studies from Santhera Pharmaceuticals. He also has received research support from government entities (Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, European Commission 7th Framework Programme) and from commercial entities (Santhera Pharmaceuticals; Actelion Pharmaceuticals, Ltd; H. Lundbeck A/S). T. Klopstock serves on scientific advisory boards for commercial entities (Santhera Pharmaceuticals; Actelion Pharmaceuticals, Ltd) and for nonprofit entities (Center for Rare Diseases, Bonn, Germany; Hoffnungsbaum e.V., Germany). He has received speaker honoraria and travel costs from commercial entities (Dr. Willmar Schwabe GmbH &amp; Co. KG; Eisai Japan; Santhera Pharmaceuticals; Actelion Pharmaceuticals, Ltd) and performs consultancies for the Gerson Lehrman Group, USA.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu-Wai-Man</surname><given-names>P</given-names></name><name><surname>Griffiths</surname><given-names>PG</given-names></name><name><surname>Chinnery</surname><given-names>PF</given-names></name></person-group>
<article-title>Mitochondrial optic neuropathies—disease mechanisms and therapeutic strategies</article-title>. 
<source>Prog Retin Eye Res.</source>
<year>2011</year>;
<volume>30</volume>:
<fpage>81</fpage>–
<lpage>114</lpage><pub-id pub-id-type="pmid">21112411</pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fraser</surname><given-names>JA</given-names></name><name><surname>Biousse</surname><given-names>V</given-names></name><name><surname>Newman</surname><given-names>NJ</given-names></name></person-group>
<article-title>The neuro-ophthalmology of mitochondrial disease</article-title>. 
<source>Surv Ophthalmol.</source>
<year>2010</year>;
<volume>55</volume>:
<fpage>299</fpage>–
<lpage>334</lpage><pub-id pub-id-type="pmid">20471050</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sadun</surname><given-names>AA</given-names></name><name><surname>La Morgia</surname><given-names>C</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name></person-group>
<article-title>Leber's hereditary optic neuropathy</article-title>. 
<source>Curr Treat Options Neurol.</source>
<year>2011</year>;
<volume>13</volume>:
<fpage>109</fpage>–
<lpage>117</lpage><pub-id pub-id-type="pmid">21063922</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Ross-Cisneros</surname><given-names>FN</given-names></name><name><surname>Sadun</surname><given-names>AA</given-names></name></person-group>
<article-title>Mitochondrial dysfunction as a cause of optic neuropathies</article-title>. 
<source>Prog Retin Eye Res.</source>
<year>2004</year>;
<volume>23</volume>:
<fpage>53</fpage>–
<lpage>89</lpage><pub-id pub-id-type="pmid">14766317</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sadun</surname><given-names>AA</given-names></name><name><surname>Win</surname><given-names>PH</given-names></name><name><surname>Ross-Cisneros</surname><given-names>FN</given-names></name><name><surname>Walker</surname><given-names>SO</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name></person-group>
<article-title>Leber's hereditary optic neuropathy differentially affects smaller axons in the optic nerve</article-title>. 
<source>Trans Am Ophthalmol Soc.</source>
<year>2000</year>;
<volume>98</volume>:
<fpage>223</fpage>–
<lpage>232</lpage><pub-id pub-id-type="pmid">11190025</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Grigsby</surname><given-names>SS</given-names></name><name><surname>Vingrys</surname><given-names>AJ</given-names></name><name><surname>Benes</surname><given-names>SC</given-names></name><name><surname>King-Smith</surname><given-names>PE</given-names></name></person-group>
<article-title>Correlation of chromatic, spatial, and temporal sensitivity in optic nerve disease</article-title>. 
<source>Invest Ophthalmol Vis Sci.</source>
<year>1991</year>;
<volume>32</volume>:
<fpage>3252</fpage>–
<lpage>3262</lpage><pub-id pub-id-type="pmid">1748555</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ventura</surname><given-names>DF</given-names></name><name><surname>Gualtieri</surname><given-names>M</given-names></name><name><surname>Oliveira</surname><given-names>AGF</given-names></name><name><surname>Costa</surname><given-names>MF</given-names></name><name><surname>Quiros</surname><given-names>P</given-names></name><name><surname>Sadun</surname><given-names>F</given-names></name><name><surname>de Negri</surname><given-names>AM</given-names></name><name><surname>Salomao</surname><given-names>SR</given-names></name><name><surname>Berezovsky</surname><given-names>A</given-names></name><name><surname>Sherman</surname><given-names>J</given-names></name><name><surname>Sadun</surname><given-names>AA</given-names></name><name><surname>Valerio Carelli</surname><given-names>V</given-names></name></person-group>
<article-title>Male prevalence of acquired color vision defects in asymptomatic carriers of Leber's hereditary optic neuropathy</article-title>. 
<source>Invest Ophthalmol Vis Sci.</source>
<year>2007</year>;
<volume>48</volume>:
<fpage>2362</fpage>–
<lpage>2370</lpage><pub-id pub-id-type="pmid">17460303</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harding</surname><given-names>AE</given-names></name><name><surname>Sweeney</surname><given-names>MG</given-names></name><name><surname>Govan</surname><given-names>GG</given-names></name><name><surname>Riordan-Eva</surname><given-names>P</given-names></name></person-group>
<article-title>Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation</article-title>. 
<source>Am J Hum Genet.</source>
<year>1995</year>;
<volume>57</volume>:
<fpage>77</fpage>–
<lpage>86</lpage><pub-id pub-id-type="pmid">7611298</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riordan-Eva</surname><given-names>P</given-names></name><name><surname>Sanders</surname><given-names>MD</given-names></name><name><surname>Govan</surname><given-names>GG</given-names></name><name><surname>Sweeney</surname><given-names>MG</given-names></name><name><surname>Da Costa</surname><given-names>J</given-names></name><name><surname>Harding</surname><given-names>AE</given-names></name></person-group>
<article-title>The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation</article-title>. 
<source>Brain</source>. 
<year>1995</year>;
<volume>118</volume>:
<fpage>319</fpage>–
<lpage>337</lpage><pub-id pub-id-type="pmid">7735876</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zanna</surname><given-names>C</given-names></name><name><surname>Ghelli</surname><given-names>A</given-names></name><name><surname>Porcelli</surname><given-names>AM</given-names></name><name><surname>Martinuzzi</surname><given-names>A</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Rugolo</surname><given-names>M</given-names></name></person-group>
<article-title>Caspase-independent death of Leber's hereditary optic neuropathy cybrids is driven by energetic failure and mediated by AIF and endonuclease G</article-title>. 
<source>Apoptosis</source>. 
<year>2005</year>;
<volume>10</volume>:
<fpage>997</fpage>–
<lpage>1007</lpage><pub-id pub-id-type="pmid">16151635</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baracca</surname><given-names>A</given-names></name><name><surname>Solaini</surname><given-names>G</given-names></name><name><surname>Sgarbi</surname><given-names>G</given-names></name><name><surname>Lenaz</surname><given-names>G</given-names></name><name><surname>Baruzzi</surname><given-names>A</given-names></name><name><surname>Schapira</surname><given-names>AHV</given-names></name><name><surname>Martinuzzi</surname><given-names>A</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name></person-group>
<article-title>Severe impairment of complex I-driven adenosine triphosphate synthesis in Leber hereditary optic neuropathy cybrids</article-title>. 
<source>Arch Neurol.</source>
<year>2005</year>;
<volume>62</volume>:
<fpage>730</fpage>–
<lpage>736</lpage><pub-id pub-id-type="pmid">15883259</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yu-Wai-Man</surname><given-names>P</given-names></name><name><surname>Griffiths</surname><given-names>PG</given-names></name><name><surname>Hudson</surname><given-names>G</given-names></name><name><surname>Chinnery</surname><given-names>PF</given-names></name></person-group>
<article-title>Inherited mitochondrial optic neuropathies</article-title>. 
<source>J Med Genet.</source>
<year>2009</year>;
<volume>46</volume>:
<fpage>145</fpage>–
<lpage>158</lpage><pub-id pub-id-type="pmid">19001017</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spruijt</surname><given-names>L</given-names></name><name><surname>Kolbach</surname><given-names>DN</given-names></name><name><surname>de Coo</surname><given-names>RF</given-names></name><name><surname>Plomp</surname><given-names>A</given-names></name><name><surname>Bauer</surname><given-names>NJ</given-names></name><name><surname>Smeets</surname><given-names>HJ</given-names></name><name><surname>De Die-Smulders</surname><given-names>C</given-names></name></person-group>
<article-title>Influence of mutation type on clinical expression of Leber hereditary optic neuropathy</article-title>. 
<source>Am J Ophthalmol.</source>
<year>2006</year>;
<volume>141</volume>:
<fpage>676</fpage>–
<lpage>682</lpage><pub-id pub-id-type="pmid">16564802</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mashima</surname><given-names>Y</given-names></name><name><surname>Hiida</surname><given-names>Y</given-names></name><name><surname>Oguchi</surname><given-names>Y</given-names></name></person-group>
<article-title>Remission of Leber's hereditary optic neuropathy with idebenone</article-title>. 
<source>Lancet</source>. 
<year>1992</year>;
<volume>340</volume>:
<fpage>368</fpage>–
<lpage>369</lpage><pub-id pub-id-type="pmid">1353825</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Barboni</surname><given-names>P</given-names></name><name><surname>Zacchini</surname><given-names>A</given-names></name><name><surname>Mancini</surname><given-names>R</given-names></name><name><surname>Monari</surname><given-names>L</given-names></name><name><surname>Cevoli</surname><given-names>S</given-names></name><name><surname>Liguori</surname><given-names>R</given-names></name><name><surname>Sensi</surname><given-names>M</given-names></name><name><surname>Lugaresi</surname><given-names>E</given-names></name><name><surname>Montagna</surname><given-names>P</given-names></name></person-group>
<article-title>Leber's hereditary optic neuropathy (LHON) with 14484/ND6 mutation in a North African patient</article-title>. 
<source>J Neurol Sci.</source>
<year>1998</year>;
<volume>160</volume>:
<fpage>183</fpage>–
<lpage>188</lpage><pub-id pub-id-type="pmid">9849804</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Valentino</surname><given-names>ML</given-names></name><name><surname>Liguori</surname><given-names>R</given-names></name><name><surname>Meletti</surname><given-names>S</given-names></name><name><surname>Vetrugno</surname><given-names>R</given-names></name><name><surname>Provini</surname><given-names>F</given-names></name><name><surname>Mancardi</surname><given-names>GL</given-names></name><name><surname>Bandini</surname><given-names>F</given-names></name><name><surname>Baruzzi</surname><given-names>A</given-names></name><name><surname>Montagna</surname><given-names>P</given-names></name></person-group>
<article-title>Leber's hereditary optic neuropathy (LHON/11778) with myoclonus: report of two cases</article-title>. 
<source>J Neurol Neurosurg Psychiatry.</source>
<year>2001</year>;
<volume>71</volume>:
<fpage>813</fpage>–
<lpage>816</lpage><pub-id pub-id-type="pmid">11723211</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cortelli</surname><given-names>P</given-names></name><name><surname>Montagna</surname><given-names>P</given-names></name><name><surname>Pierangeli</surname><given-names>G</given-names></name><name><surname>Lodi</surname><given-names>R</given-names></name><name><surname>Barboni</surname><given-names>P</given-names></name><name><surname>Liguori</surname><given-names>R</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Iotti</surname><given-names>S</given-names></name><name><surname>Zaniol</surname><given-names>P</given-names></name><name><surname>Lugaresi</surname><given-names>E</given-names></name><name><surname>Barbiroli</surname><given-names>B</given-names></name></person-group>
<article-title>Clinical and brain bioenergetics improvement with idebenone in a patient with Leber's hereditary optic neuropathy: a clinical and 31P-MRS study</article-title>. 
<source>J Neurol Sci.</source>
<year>1997</year>;
<volume>148</volume>:
<fpage>25</fpage>–
<lpage>31</lpage><pub-id pub-id-type="pmid">9125387</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mashima</surname><given-names>Y</given-names></name><name><surname>Kigasawa</surname><given-names>K</given-names></name><name><surname>Wakakura</surname><given-names>M</given-names></name><name><surname>Yoshihisa</surname><given-names>O</given-names></name></person-group>
<article-title>Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy?</article-title>
<source>J Neuroophthalmol.</source>
<year>2000</year>;
<volume>20</volume>:
<fpage>166</fpage>–
<lpage>170</lpage><pub-id pub-id-type="pmid">11001192</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klopstock</surname><given-names>T</given-names></name><name><surname>Yu-Wai-Man</surname><given-names>P</given-names></name><name><surname>Dimitriadis</surname><given-names>K</given-names></name><name><surname>Rouleau</surname><given-names>J</given-names></name><name><surname>Heck</surname><given-names>S</given-names></name><name><surname>Bailie</surname><given-names>M</given-names></name><name><surname>Atawan</surname><given-names>A</given-names></name><name><surname>Chattopadhyay</surname><given-names>S</given-names></name><name><surname>Schubert</surname><given-names>M</given-names></name><name><surname>Garip</surname><given-names>A</given-names></name><name><surname>Kernt</surname><given-names>M</given-names></name><name><surname>Petraki</surname><given-names>D</given-names></name><name><surname>Rummey</surname><given-names>C</given-names></name><name><surname>Leinonen</surname><given-names>M</given-names></name><name><surname>Metz</surname><given-names>G</given-names></name><name><surname>Griffiths</surname><given-names>PG</given-names></name><name><surname>Meier</surname><given-names>T</given-names></name><name><surname>Chinnery</surname><given-names>PF</given-names></name></person-group>
<article-title>A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy</article-title>. 
<source>Brain</source>. 
<year>2011</year>;
<volume>134</volume>:
<fpage>2677</fpage>–
<lpage>2686</lpage><pub-id pub-id-type="pmid">21788663</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>La Morgia</surname><given-names>C</given-names></name><name><surname>Valentino</surname><given-names>ML</given-names></name><name><surname>Rizzo</surname><given-names>G</given-names></name><name><surname>Carbonelli</surname><given-names>M</given-names></name><name><surname>De Negri</surname><given-names>AM</given-names></name><name><surname>Sadun</surname><given-names>F</given-names></name><name><surname>Carta</surname><given-names>A</given-names></name><name><surname>Guerriero</surname><given-names>S</given-names></name><name><surname>Simonelli</surname><given-names>F</given-names></name><name><surname>Sadun</surname><given-names>AA</given-names></name><name><surname>Aggarwal</surname><given-names>D</given-names></name><name><surname>Liguori</surname><given-names>R</given-names></name><name><surname>Avoni</surname><given-names>P</given-names></name><name><surname>Baruzzi</surname><given-names>A</given-names></name><name><surname>Zeviani</surname><given-names>M</given-names></name><name><surname>Montagna</surname><given-names>P</given-names></name><name><surname>Barboni</surname><given-names>P</given-names></name></person-group>
<article-title>Idebenone treatment in Leber's hereditary optic neuropathy</article-title>. 
<source>Brain</source>. 
<year>2011</year>;
<volume>134</volume>:
<fpage>e188</fpage><pub-id pub-id-type="pmid">21810891</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arden</surname><given-names>GB</given-names></name><name><surname>Wolf</surname><given-names>JE</given-names></name></person-group>
<article-title>Colour vision testing as an aid to diagnosis and management of age related maculopathy</article-title>. 
<source>Br J Ophthalmol.</source>
<year>2004</year>;
<volume>88</volume>:
<fpage>1180</fpage>–
<lpage>1185</lpage><pub-id pub-id-type="pmid">15317712</pub-id></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Quiros</surname><given-names>PA</given-names></name><name><surname>Torres</surname><given-names>RJ</given-names></name><name><surname>Salomao</surname><given-names>S</given-names></name><name><surname>Berezovsky</surname><given-names>A</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Sherman</surname><given-names>J</given-names></name><name><surname>Sadun</surname><given-names>F</given-names></name><name><surname>De Negri</surname><given-names>A</given-names></name><name><surname>Belfort</surname><given-names>R</given-names></name><name><surname>Sadun</surname><given-names>AA</given-names></name></person-group>
<article-title>Colour vision defects in asymptomatic carriers of the Leber's hereditary optic neuropathy (LHON) mtDNA 11778 mutation from a large Brazilian LHON pedigree: a case-control study</article-title>. 
<source>Br J Ophthalmol.</source>
<year>2006</year>;
<volume>90</volume>:
<fpage>150</fpage>–
<lpage>153</lpage><pub-id pub-id-type="pmid">16424523</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haefeli</surname><given-names>RH</given-names></name><name><surname>Erb</surname><given-names>M</given-names></name><name><surname>Gemperli</surname><given-names>AC</given-names></name><name><surname>Robay</surname><given-names>D</given-names></name><name><surname>Courdier-Fruh</surname><given-names>I</given-names></name><name><surname>Anklin</surname><given-names>C</given-names></name><name><surname>Dallmann</surname><given-names>R</given-names></name><name><surname>Gueven</surname><given-names>N</given-names></name></person-group>
<article-title>NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels</article-title>. 
<source>PLoS One</source>. 
<year>2011</year>;
<volume>6</volume>:
<fpage>e17963</fpage><pub-id pub-id-type="pmid">21483849</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barboni</surname><given-names>P</given-names></name><name><surname>Savini</surname><given-names>G</given-names></name><name><surname>Valentino</surname><given-names>ML</given-names></name><name><surname>Montagna</surname><given-names>P</given-names></name><name><surname>Cortelli</surname><given-names>P</given-names></name><name><surname>De Negri</surname><given-names>AM</given-names></name><name><surname>Sadun</surname><given-names>F</given-names></name><name><surname>Bianchi</surname><given-names>S</given-names></name><name><surname>Longanesi</surname><given-names>L</given-names></name><name><surname>Zanini</surname><given-names>M</given-names></name><name><surname>di Vivo</surname><given-names>A</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name></person-group>
<article-title>Retinal nerve fiber layer evaluation by optical coherence tomography in Leber's hereditary optic neuropathy</article-title>. 
<source>Ophthalmology</source>. 
<year>2005</year>;
<volume>112</volume>:
<fpage>120</fpage>–
<lpage>126</lpage><pub-id pub-id-type="pmid">15629831</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barboni</surname><given-names>P</given-names></name><name><surname>Carbonelli</surname><given-names>M</given-names></name><name><surname>Savini</surname><given-names>G</given-names></name><name><surname>do Ramos</surname><given-names>C</given-names></name><name><surname>Carta</surname><given-names>A</given-names></name><name><surname>Berezovsky</surname><given-names>A</given-names></name><name><surname>Salomao</surname><given-names>SR</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Sadun</surname><given-names>AA</given-names></name></person-group>
<article-title>Natural history of Leber's hereditary optic neuropathy: longitudinal analysis of the retinal nerve fiber layer by optical coherence tomography</article-title>. 
<source>Ophthalmology</source>. 
<year>2010</year>;
<volume>117</volume>:
<fpage>623</fpage>–
<lpage>627</lpage><pub-id pub-id-type="pmid">20031228</pub-id></mixed-citation></ref></ref-list></back></article>